Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Agora Inc (API) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Agora Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.88 (market cap $4.49B), while Agora Inc trades at $4.15 (market cap $348.77M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 12.9× Agora Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Agora Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | API | |
|---|---|---|
Market Cap | $4.49B | $348.77M |
Sector | Health | Technology |
52-Week High | $28.06 | $5.26 |
52-Week Low | $20.06 | $3.24 |
Enterprise Value | $3.69B | $101.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Agora, Inc. (API) trades at $4.11, up 2.49% today, showing improved fundamentals with a shift to profitability in 2025 after years of losses. The stock carries a bullish 60% analyst buy rating despite bearish technical signals. Recent earnings beats and strong cash flow generation highlight operational turnaround, though valuation metrics present a mixed picture with low P/B ratio but elevated P/E.
The outlook suggests potential upside from continued AI-driven growth and possible strategic moves, but risks include competitive pressures and the sustainability of recent margin improvements. Investors should weigh the attractive valuation against execution risks in the evolving conversational AI market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Agora Inc
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
Read more on API →
